Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cirmtuzumab |
Synonyms | |
Therapy Description |
Cirmtuzumab (UC-961) is a monoclonal antibody that binds to human receptor tyrosine kinase-like orphan receptor 1 (ROR1) and blocks ROR1 signaling, leading to growth inhibition in tumor cells (PMID: 26297272, PMID: 29859176, PMID: 32090643). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cirmtuzumab | UC-961 | ROR1 Antibody 7 | Cirmtuzumab (UC-961) is a monoclonal antibody that binds to human receptor tyrosine kinase-like orphan receptor 1 (ROR1) and blocks ROR1 signaling, leading to growth inhibition in tumor cells (PMID: 26297272, PMID: 29859176, PMID: 32090643). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03088878 | Phase Ib/II | Cirmtuzumab Cirmtuzumab + Ibrutinib Ibrutinib | A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | Completed | USA | 0 |
NCT02222688 | Phase I | Cirmtuzumab | UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia | Completed | USA | 0 |
NCT02860676 | Phase I | Cirmtuzumab | Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 | Completed | USA | 0 |